Impact of molecular alterations of BRAF in the pathogenesis of thyroid cancer

Mutagenesis

Volumn 29, Issue 2, 2014, Pages 131-137

  Khan, Mosin S ^a   Pandith, Arshad A ^a   Azad, Niyaz ^b   Hussain, Mahboob Ul ^c   Masoodi, Shariq R ^a   Wani, Khursheed A ^a   Andrabi, Khurshid I ^c   Mudassar, Syed ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF KASHMIR   (India)

^c Department of Endocrinology ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

BASE SEQUENCE; BLOTTING, WESTERN; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; ELECTROPHORESIS, AGAR GEL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIA; MOLECULAR SEQUENCE DATA; ODDS RATIO; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84894240252     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/get066     Document Type: Article

References (43)

1. Sarlis, N. J. and Benvenga, S. (2004) Molecular signaling in thyroid cancer. Cancer Treat. Res., 122, 237-264.
2. Sarlis, N. J. (2000) Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects. Rev. Endocr. Metab. Disord., 1, 183-196.
3. Hundahl, S. A., Fleming, I. D., Fremgen, A. M. and Menck, H. R. (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer, 83, 2638-2648. (Pubitemid 29019586)
4. Xing, M., Westra, W. H., Tufano, R. P., et al. (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab., 90, 6373-6379. (Pubitemid 41759286)
5. Kumar, R., Angelini, S., Czene, K., Sauroja, I., Hahka-Kemppinen, M., Pyrh?en, S. and Hemminki, K. (2003) BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res., 9, 3362-3368. (Pubitemid 37082731)
6. Davies, H., Bignell, G. R., Cox, C., et al. (2002) Mutations of the BRAF gene in human cancer. Nature, 417, 949-954. (Pubitemid 34716871)
7. Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E. and Fagin, J. A. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res., 63, 1454-1457. (Pubitemid 36373628)
8. Cohen, Y., Xing, M., Mambo, E., et al. (2003) BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst., 95, 625-627. (Pubitemid 36553510)
9. Giordano, T. J., Kuick, R., Thomas, D. G., et al. (2005) Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene, 24, 6646-6656. (Pubitemid 41486795)
10. Chevillard, S., Ugolin, N., Vielh, P., Ory, K., Levalois, C., Elliott, D., Clayman, G. L. and El-Naggar, A. K. (2004) Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin. Cancer Res., 10, 6586-6597. (Pubitemid 39346555)
11. Kondo, T., Nakazawa, T., Murata, S., Kurebayashi, J., Ezzat, S., Asa, S. L. and Katoh, R. (2007) Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum. Pathol., 38, 1810-1818. (Pubitemid 350179928)
12. Ciampi, R., Knauf, J. A., Kerler, R., Gandhi, M., Zhu, Z., Nikiforova, M. N., Rabes, H. M., Fagin, J. A. and Nikiforov, Y. E. (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest., 115, 94-101. (Pubitemid 40385509)
13. Robinson, M. J. and Cobb, M. H. (1997) Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol., 9, 180-186. (Pubitemid 27135985)
14. Marais, R., Light, Y., Paterson, H. F., Mason, C. S. and Marshall, C. J. (1997) Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem., 272, 4378-4383. (Pubitemid 27078513)
15. Emma, R. (2011) BRAF V600E: implications for carcinogenesis and molecular therapy. Mol. Cancer Ther., 10, 385-394.
16. Kyung-Hee, K. (2005) Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimotos thyroiditis. Pathol. Int., 55, 540-545.
17. Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B. and Prinz, R. A. (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res., 63, 4561-4567. (Pubitemid 36951030)
18. Trovisco, V., Vieira de Castro, I., Soares, P., M?imo, V., Silva, P., Magalh?s, J., Abrosimov, A., Guiu, X. M. and Sobrinho-Sim-s, M. (2004) BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J. Pathol., 202, 247-251. (Pubitemid 38208663)
19. Soares, P., Trovisco, V., Rocha, A. S., et al. (2004) BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch., 444, 572-576. (Pubitemid 38858382)
20. Jonklaas, J., Sarlis, N. J., Litofsky, D., et al. (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid, 16, 1229-1242. (Pubitemid 46080167)
21. Braga, M., Ringel, M. D. and Cooper, D. S. (2001) Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J. Clin. Endocrinol. Metab., 86, 5148-5151. (Pubitemid 33070229)
22. Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A. and Braverman, L. E. (2002) Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab., 87, 489-499. (Pubitemid 34158210)
23. Kratzsch, J., Fiedler, G. M., Leichtle, A., Br?el, M., Buchbinder, S., Otto, L., Sabri, O., Matthes, G. and Thiery, J. (2005) New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid. Clin. Chem., 51, 1480-1486. (Pubitemid 41060881)
24. Boelaert, K., Horacek, J., Holder, R. L., Watkinson, J. C., Sheppard, M. C. and Franklyn, J. A. (2006) Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J. Clin. Endocrinol. Metab., 91, 4295-4301. (Pubitemid 44833401)
25. Haymart, M. R., Repplinger, D. J., Leverson, G. E., Elson, D. F., Sippel, R. S., Jaume, J. C. and Chen H. (2008) Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J. Clin. Endocrinol. Metab., 93, 809-814. (Pubitemid 351398557)
26. Xing, M. (2010) Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol. Cell. Endocrinol., 321, 86-93.
27. Pomerance, M., Abdullah, H. B., Kamerji, S., Correze, C. and Blondeau, J. P. (2000) Thyroid-stimulating hormone and cyclic AMP activate p38 mitogen-activated protein kinase cascade. Involvement of protein kinase A, rac1, and reactive oxygen species. J. Biol. Chem., 275, 40539-40546. (Pubitemid 32064691)
28. Tsygankova, O. M., Saavedra, A., Rebhun, J. F., Quilliam, L. A. and Meinkoth, J. L. (2001) Coordinated regulation of Rap1 and thyroid differentiation by cyclic AMP and protein kinase A. Mol. Cell. Biol., 21, 1921-1929. (Pubitemid 32479616)
29. Namba, H., Nakashima, M., Hayashi, T., et al. (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab., 88, 4393-4397. (Pubitemid 37153748)
30. Begum, S., Rosenbaum, E., Henrique, R., Cohen, Y., Sidransky, D. and Westra, W. H. (2004) BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod. Pathol., 17, 1359-1363. (Pubitemid 39472990)
31. Hay, I. D., Bergstralh, E. J., Goellner, J. R., Ebersold, J. R. and Grant, C. S. (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery, 114, 1050-7; discussion 1057.
32. Fonseca, E., Soares, P., Rossi, S. and Sobrinho-Sim-s, M. (1997) Prognostic factors in thyroid carcinomas. Verh. Dtsch. Ges. Pathol., 81, 82-96.
33. Gilliland, F. D., Hunt, W. C., Morris, D. M. and Key, C. R. (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer, 79, 564-573. (Pubitemid 27051783)
34. Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O. H., Duh, Q. Y., Shibru, D., Bastian, B. and Griffin, A. (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg., 246, 466-70; discussion 470. (Pubitemid 47312140)
35. Yip, L., Nikiforova, M. N., Carty, S. E., et al. (2009) Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery, 146, 1215-1223.
36. Xinying, L. (2009) BRAF mutation in papillary thyroid carcinoma. Int. J. Clin. Exp. Med., 5, 310-315.
37. Fugazzola, L., Puxeddu, E., Avenia, N., et al. (2006) Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr. Relat. Cancer, 13, 455-464. (Pubitemid 43886668)
38. Jo, Y. S., Li, S., Song, J. H., et al. (2006) Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J. Clin. Endocrinol. Metab., 91, 3667-3670. (Pubitemid 44402153)
39. Liu, D., Liu, Z., Condouris, S. and Xing, M. (2007) BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAFmutant papillary thyroid cancer cells. J. Clin. Endocrinol. Metab., 92, 2264-2271. (Pubitemid 46997132)
40. Rodolico, V., Cabibi, D., Pizzolanti, G., et al. (2007) BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid (Pubitemid 47435591)
41. Ciampi, R. and Nikiforov, Y. E. (2005) Alterations of the BRAF gene in thyroid tumors. Endocr. Pathol., 16, 163-172. (Pubitemid 41687187)
42. Ciampi, R., Zhu, Z. and Nikiforov, Y. E. (2005) BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr. Pathol., 16, 99-106.
43. Feng, L., Li, M., Zhang, Q. P., Piao, Z. A., Wang, Z. H. and Lv, S. (2011) Utility of BRAF protein overexpression in predicting the metastasis potential of papillary thyroid carcinoma. Oncol. Lett., 2, 59-63.